Werner Syndrome NR Trial: What NAD+ Deficit May Change

Nicotinamide riboside (NR) may make the most sense when there is a real NAD+ problem to solve. A small randomized trial in Werner syndrome—a genetic disorder that causes early vascular disease, metabolic dysfunction, and premature cellular aging—offers a rare human test of that idea. It does not show that healthy people should take NR for longevity. It asks a sharper question: when NAD+ depletion is severe, measurable, and driven by a known disease mechanism, can an oral precursor help?

That distinction matters because NR reliably raises circulating NAD+ in humans, while improvements in strength, insulin sensitivity, vascular function, or cognition remain inconsistent in generally healthy adults. Raising a blood biomarker and improving a patient-relevant outcome are different jobs. Supplements are often very good at the first.

A rare trial in an extreme NAD+ deficit state

Werner syndrome results from loss-of-function mutations in WRN, a gene encoding a helicase involved in genome maintenance. People with the condition develop features associated with aging much earlier than usual, including vascular disease, diabetes, skin ulcers, and multisystem decline. In Shoji et al.'s 2025 double-blind, randomized, crossover, placebo-controlled trial, 11 people enrolled, 9 were randomized, and 6 completed the full-analysis/per-protocol assessment.

The participants were about 47 years old on average, but their baseline arterial stiffness was high: cardio-ankle vascular index (CAVI) averaged 8.28 on the right and 8.05 on the left. Many participants also had diabetes, and some had active, difficult-to-treat skin ulcers. The trial evaluated vascular, skin, sarcopenia, and metabolic outcomes while comparing NR with placebo in a crossover design.

This is the first randomized intervention study of an NAD+ precursor in a human progeroid syndrome. It is an impressive effort in a rare, medically burdensome disease. It is also a six-person per-protocol analysis. That leaves very little room for certainty about effect size, secondary outcomes, or which patients benefited.

The available study details do not establish verified treatment-period changes in CAVI, ulcer outcomes, renal markers, confidence intervals, or p values. Those omissions matter. A trial can generate a biologically important signal without supplying a precise estimate of clinical benefit. Readers should resist filling those gaps with the usual "NAD+ restores youth" fan fiction.

Why Werner syndrome differs from ordinary aging

The biological rationale is unusually specific. WRN deficiency can create a two-sided NAD+ problem: persistent DNA damage activates PARP1, an enzyme that consumes NAD+, while WRN-related changes suppress NMNAT1, an enzyme needed for NAD+ biosynthesis. In other words, demand rises as replenishment falls.

Lautrup et al.'s 2025 cell-model study localized the deficit in WRN-deficient cells to the mitochondrial NAD+ pool and linked it to impaired proliferation and premature senescence. This is preclinical evidence, not proof that an NR capsule restores mitochondrial NAD+ in patients. Still, it gives the trial a stronger rationale than the generic claim that everyone loses NAD+ with age.

Normal aging has different biology. NAD+ levels decline with age, and the salvage-pathway enzyme NAMPT is a major rate-limiting step in NAD+ synthesis, as reviewed by Khaidizar and colleagues. Age-related changes may also involve inflammation and CD38 NADase activity. That gradual, heterogeneous process is not equivalent to a genetic disorder combining PARP1 overconsumption with impaired biosynthesis. Same molecule; different plumbing.

What human trials show outside Werner syndrome

Human studies support one narrow conclusion with considerable consistency: oral NR and nicotinamide mononucleotide (NMN) raise plasma or whole-blood NAD+. A 2026 PRISMA-guided review by Gallagher et al. found that this pharmacodynamic effect replicates more reliably than functional benefits in anti-aging and wellness studies. Plasma NAD+ is useful evidence that the compound was absorbed and metabolized. It does not tell us whether a depleted mitochondrial pool, a muscle cell, or an artery received enough NAD+ to alter disease.

There are encouraging results in groups with defined physiological stress or metabolic impairment. In a 10-week double-blind randomized trial, Yoshino et al. gave 250 mg/day of NMN to 25 postmenopausal women with prediabetes and reported improved skeletal-muscle insulin signaling on transcriptomic biopsy analysis. This was NMN, not NR, and the population had prediabetes; neither detail is decorative.

Likewise, Liao et al. studied 48 young and middle-aged recreationally trained runners in a six-week, double-blind, four-arm trial. Participants received placebo or 300, 600, or 1,200 mg/day of NMN while training. NMN improved aerobic-capacity measures in that setting. Training creates a high-demand physiological state, but it does not turn the trial into evidence for sedentary adults taking NR.

NR-specific evidence also suggests that oral dosing can affect biology beyond plasma. Vreones et al. reported higher NAD+ and lower neurodegeneration-related biomarkers in plasma extracellular vesicles enriched for neuronal origin after oral NR. Those vesicles are an indirect proxy for neuronal tissue. The finding supports tissue penetration more than it supports a cognitive benefit; the study did not establish that NR improves cognitive performance.

Why the broader anti-aging case remains unsettled

The larger evidence base has not produced a consistent functional payoff. A 2025 systematic review and meta-analysis by Prokopidis et al. found generally small, heterogeneous effects of NMN and NR on muscle mass and function in middle-aged and older adults, without a consistent significant improvement in muscle strength or mass. A 2026 meta-analysis of NMN trials in middle-aged and older people likewise found modest, variable effects on muscle and liver outcomes.

Those summaries have their own limitation: pooling NMN and NR can blur meaningful differences in bioavailability, conversion, and tissue distribution. Palmer et al. reviewed these pharmacokinetic differences and cautioned against treating the precursors as interchangeable. The strongest positive human trials cited here used NMN. The Werner syndrome study used NR. Any claim that one result proves the other compound works would outrun the evidence.

Other proposed applications remain earlier still. Retinal disease reviews describe NAD+ depletion and promising preclinical interventions, but no completed clinical trial establishes a systemic NR benefit for retinal disease. Brown-fat experiments include human tissue and do not establish meaningful thermogenesis in living people at standard oral doses. Cognitive reviews remain dominated by animal work and call for controlled human trials. Liver disease deserves particular restraint: Dall et al. argue that the relationship between NAD+ depletion and fatty liver can be causal in some settings and correlative in others.

The design limits are part of the finding

The Werner syndrome trial used a crossover design because rare diseases make conventional large parallel trials difficult. Each participant can serve as their own comparator, which improves efficiency. But Werner syndrome progresses over time. Disease changes between treatment periods can mimic, mask, or distort a treatment effect, and ordinary carryover adjustments may not solve that problem.

Generalizability is another constraint. About 88.9% of enrolled participants carried the c.3319-1G>C WRN mutation, common in the Japanese Werner syndrome population. Other WRN mutations could affect PARP1 activity, NMNAT1 regulation, or mitochondrial NAD+ biology differently. Six people with a concentrated mutation spectrum cannot answer for all Werner syndrome, much less for healthy adults.

No prospective human randomized trial has yet stratified participants by baseline NAD+ status and tested whether those with lower NAD+ derive larger functional benefits from NR or NMN. That is the study the field needs. It would measure more than plasma NAD+, distinguish NR from NMN, prespecify patient-relevant outcomes, and test whether a biochemical deficit predicts response.

What to do with this evidence

The Werner syndrome trial is a signal from an extreme disease model, not an NR recommendation for the general public. Its value lies in the hypothesis it sharpens: NAD+ precursors may have the best chance of producing functional benefits when a person has substantial NAD+ depletion or elevated demand caused by disease, metabolic dysfunction, or another defined stressor.

For people with prediabetes, insulin resistance, advanced age with significant functional decline, or a diagnosed condition linked to NAD+ biology, the rationale for clinical research is stronger than it is for a healthy 35-year-old looking for a longevity upgrade. Stronger rationale is still not a prescription. For healthy adults with normal metabolic function and no measured deficit, NR can raise circulating NAD+, but current trials do not show a reliable, meaningful anti-aging benefit beyond that biomarker change.

The sensible conclusion is narrower than the marketing: NR deserves better stratified trials, and Werner syndrome offers a compelling reason to run them. It does not make NAD+ depletion the universal explanation for aging—or NR the universal answer.